CD4 and neoplasm: Recent studies have shown that cDC1s are critically important for anti-tumor immune responses and that their presence in the TME positively correlates to OS and clinical responses upon PD-1 monoclonal antibody (mAb) in melanoma.49, 50, 51 Classically, cDC2s mainly activate CD4+ T cells.